SAPHNELO systemic lupus erythematosus Japan Post-Marketing Surveillance (PMS)

Study identifier:D3461C00022

ClinicalTrials.gov identifier:NCT05141201

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Saphnelo for Intravenous Infusion 300 mg Specific Use result study All Patient Investigation in patients with systemic lupus erythematosus

Medical condition

Lupus Erythematosus, Systemic

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1620

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 21 Dec 2021
Estimated Primary Completion Date: 30 Nov 2025
Estimated Study Completion Date: 30 Nov 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria